Cargando…
A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T cell checkpoints, is a promising new therapy for advanced malignant melanoma and NSCLC. However, patients with autoimmune diseases were excluded at the clinical trial using such immune checkpoint inhibitor, becaus...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Japan
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498278/ https://www.ncbi.nlm.nih.gov/pubmed/31149453 http://dx.doi.org/10.1007/s13691-016-0256-8 |